For individuals facing Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of this treatment and the formulated version represents a genuine change. These novel therapies preserve the transthyretin protein, halting its harmful build-up and reducing the severity of the disease . People are now seeing positive outcom